Metformin/Rosiglitazone

DEA Class; Rx

Common Brand Names; Avandamet

  • Antidiabetics, Biguanides/Thiazolidinediones

Oral combination of metformin, a biguanide, and rosiglitazone, a thiazolidinedione (TZD)
Used in adults for type 2 diabetes mellitus; rosiglitazone is not to be used with insulin
Risk of lactic acidosis due to metformin is low; TZDs may cause or exacerbate heart failure; monitor closely

Indicated for the treatment of type 2 diabetes mellitus not controlled by diet and exercise.

For use when initial treatment with rosiglitazone alone does not result in adequate glycemic control.
Switching patients already taking rosiglitazone plus metformin to the combination product.

Hypersensitivity to rosiglitazone or metformin

Heart failure NYHA Class III-IV

Metabolic acidosis, including diabetic ketoacidosis with or without coma

Severe renal disease: eGFR <30 ml/min/1.73 m²

Nursing women

  • Edema (6% to 25% )
  • Upper respiratory infections (16-20%)
  • Diarrhea (12.7% to 14%)
  • Hypoglycemia (12% )
  • Anemia (4% to 7%)
  • Fatigue (6%)
  • Headache (6%)
  • Sinusitis (6%)
  • Arthralgia (5%)
  • Back pain (5%)
  • Viral infection (5%)
  • Angioedema (rare )
  • Congestive heart failure
  • Death, from cardiovascular causes
  • Stevens-Johnson syndrome (rare )
  • Lactic acidosis (rare )
  • Hepatotoxicity (rare)
  • Anaphylaxis (rare )
  • Diabetic macular edema
  • Pleural effusion
  • Pulmonary edema

Metformin

  • Cholestatic, hepatocellular, and mixed hepatocellular liver injury

Risk of severe hypoglycemia especially in elderly, debilitated or malnourished, adrenal or pituitary insufficiency, dehydration, heavy alcohol use, hypoxic states, hepatic/renal impairment, stress due to infection, fever, trauma, or surgery

Rare lactic acidosis may occur due to metformin accumulation; fatal in approx 50% of cases; risk increases with age, degree of renal dysfunction, and with unstable or acute CHF; if metformin-associated lactic acidosis suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of therapy; in patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable, with a clearance of up to170 mL/minute under good hemodynamic conditions); hemodialysis has often resulted in reversal of symptoms and recovery

Edema; thiazolidinediones, which are peroxisome proliferator-activated receptor (PPAR) gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin; not recommended for use with insulin

Withholding of food and fluids during surgical or other procedures may increase risk for volume depletion, hypotension, and renal impairment; therapy should be temporarily discontinued while patients have restricted food and fluid intake

Several of the postmarketing cases of metformin-associated lactic acidosis occurred in setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia); cardiovascular collapse (shock) acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia; discontinue therapy when such events occur

Therapy with thiazolidinediones may result in ovulation in premenopausal anovulatory women

Rosiglitazone: Associated with rare cases of new onset or worsening of macular edema

Pregnancy Category: C

Lactation: not known if crosses into breast milk, avoid

Adults

8 mg/day PO rosiglitazone with 2000 mg/day PO metformin.

Elderly

In general do not titrate to the adult maximum dosage of 8 mg/day PO rosiglitazone with 2000 mg/day PO metformin.

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Metformin/rosiglitazone

tablet

  • 500mg/2mg
  • 500mg/4mg
  • 1000mg/2mg
  • 1000mg/4mg

About the Author

You may also like these

0